¼¼°èÀÇ ¸®Æ÷Á» µ¶¼Ò·çºñ½Å ½ÃÀå - ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : Á¦Ç°º°, ¿ëµµº°, À¯Åë ä³Îº°, Áö¿ªº°, ºÎ¹® ¿¹Ãø(2024-2030³â)
Liposomal Doxorubicin Market Size, Share & Trends Analysis Report By Product, By Application (Multiple Myeloma, Ovarian Cancer, Breast Cancer), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
»óǰÄÚµå : 1553623
¸®¼­Ä¡»ç : Grand View Research, Inc.
¹ßÇàÀÏ : 2024³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 100 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,950 £Ü 8,191,000
Unprintable PDF & Excel (Single User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» 1Àθ¸ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 6,950 £Ü 9,568,000
Printable PDF & Excel (5-User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» µ¿ÀÏ ±â¾÷ ³» µ¿ÀÏ ºÎ¼­¿¡¼­ ÃÖ´ë 5¸í±îÁö »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â °¡´ÉÇÕ´Ï´Ù.
US $ 8,950 £Ü 12,321,000
Printable PDF & Excel (Enterprise License) help
º¸°í¼­ ±¸¸Å ±â¾÷ ¹× ±× ÀÚȸ»ç, °ü°è»ç°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀ̸ç, PDF ¹× ¿¢¼¿ ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¸®Æ÷Á» µ¶¼Ò·çºñ½Å ½ÃÀåÀÇ ¼ºÀå°ú µ¿Çâ

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é ¸®Æ÷Á» µ¶¼Ò·çºñ½Å ¼¼°è ½ÃÀå ±Ô¸ð´Â 2024-2030³â¿¡ °ÉÃÄ CAGR 6.3%¸¦ ±â·ÏÇßÀ¸¸ç, 2030³â¿¡´Â 18¾ï 9,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.

¹Ì±¹ FDA¿Í À¯·´ ÀǾàûÀÇ ½ÂÀÎÀ» ±â´Ù¸®´Â ´Ù¾çÇÑ ÆÄÀÌÇÁ¶óÀÎ Á¦Ç°ÀÇ Á¸Àç´Â ÀÌ ½ÃÀåÀÇ ÁÖ¿ä Æ¯¼º Áß ÇϳªÀÔ´Ï´Ù. ÃÖÃÊÀÇ ¸®Æ÷Á» µ¶¼Ò·çºñ½Å Á¦ÇüÀº 1995³â¿¡ Ãâ½ÃµÇ¾ú½À´Ï´Ù. Janssen ProductsÀÇ Doxil/Caelyx¿Í Teva Pharmaceutical LaboratoriesÀÇ LP & MyocetÀÔ´Ï´Ù. ¸®Æ÷Á» µ¶¼Ò·çºñ½ÅÀÇ »óǰ¸íÀÎ DoxilÀº ÇöÀç °³¹ß ÁßÀ̸ç, »óǰȭ ÈÄ ÇâÈÄ 3-4³â ¸¸¿¡ Å« °¡Ä¡¸¦ âÃâÇÒ °ÍÀ¸·Î ±â´ëµÇ°í ÀÖ½À´Ï´Ù.

¹Ì±¹ FDA¿¡ ÀÇÇÑ ÀǾàǰ Á¦Á¶ ½ÂÀÎ Áõ°¡µµ ½ÃÀåÀ» ¹Ð¾î¿Ã¸± °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¡ÀÌÁî °ü·Ã Ä«Æ÷½ÃÀ°Á¾, ´Ù¹ß¼º °ñ¼öÁ¾, ½Å°æ¸ð¼¼Æ÷Á¾, °ñÀ°Á¾, ³­¼Ò¾Ï µî ´Ù¾çÇÑ Áúº´¿¡ ´ëÇÑ ÀÌ·¯ÇÑ ¾à¹°ÀÇ ÀûÀÀ È®´ë°¡ ¼ö¿äÀÇ ¼ºÀåÀ» ÀǹÌÇÕ´Ï´Ù. °Ç°­¿¡ ºÎÁ¤ÀûÀÎ ¿µÇâÀ» ±Øº¹Çϱâ À§ÇÑ ¾à¹° Á¦ÇüÀÇ ±â¼úÀû Áøº¸¿Í ÄÚÆÃµÈ ³ª³ëÀÔÀÚ¿Í °°Àº ´Ù¾çÇÑ À¯ÇüÀÇ ¾à¹° Àü´Þ ½Ã½ºÅÛÀÇ Ã¤¿ëÀº ¾à¹° ¼ö¿ä¸¦ ÃËÁøÇÏ´Â ¸Å¿ì Áß¿äÇÑ ¿äÀÎÀÇ ÀϺÎÀÔ´Ï´Ù.

¸®Æ÷Á» µ¶¼Ò·çºñ½ÅÀº ÁÖ·Î °ñ¼öÁ¾, Ä«Æ÷Áö À°Á¾, ³­¼Ò¾ÏÀÇ Ä¡·á·Î ½ÂÀεǾú½À´Ï´Ù. ±×·¯³ª ´Ù¸¥ Áúº´¿¡¼­µµ ³Î¸® »ç¿ëµÇ±â ¶§¹®¿¡ 2015³â¿¡´Â À¯¹æ¾ÏÀÌ 21.2%ÀÇ ÃÖ´ë ¼öÀÍÀ» Â÷ÁöÇß½À´Ï´Ù. À¯¹æ¾ÏÀÇ À¯º´·ü Áõ°¡´Â È­Çпä¹ý¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î À̾îÁö°í ÀÖÀ¸¸ç, ÀÌ´Â ¼öÀÍ Á¡À¯À²ÀÇ ´ëºÎºÐÀ» Â÷ÁöÇÕ´Ï´Ù. À¯¹æ¾Ï À̿ܿ¡µµ ³­¼Ò¾Ï, ´Ù¹ß¼º °ñ¼öÁ¾, °£¾Ï µîµµ 2015³â¿¡´Â Å« Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. °£¾Ï Ä¡·á¿¡¼­ µ¶¼Ò·çºñ½ÅÀÇ »ç¿ëÀº ±Þ¼ÓÈ÷ È®´ëµÇ°í ÀÖÀ¸¸ç, ÀÌ ¿ëµµ´Â ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸¥ CAGR 7.8%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸®Æ÷Á» µ¶¼Ò·çºñ½Å ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¸®Æ÷Á» µ¶¼Ò·çºñ½Å ½ÃÀåÀÇ º¯¼ö, µ¿Çâ, ¹üÀ§

Á¦4Àå ¸®Æ÷Á» µ¶¼Ò·çºñ½Å ½ÃÀå : Á¦Ç°º°, ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦5Àå ¸®Æ÷Á» µ¶¼Ò·çºñ½Å ½ÃÀå : ¿ëµµº°, ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦6Àå ¸®Æ÷Á» µ¶¼Ò·çºñ½Å ½ÃÀå : À¯Åë ä³Îº°, ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦7Àå ¸®Æ÷Á» µ¶¼Ò·çºñ½Å ½ÃÀå : Áö¿ªº°, ÃßÁ¤¡¤µ¿Ç⠺м®

JHS
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Liposomal Doxorubicin Market Growth & Trends:

The global liposomal doxorubicin market size is expected to reach USD 1.89 billion by 2030, registering a CAGR of 6.3% from 2024 to 2030, according to a new report by Grand View Research, Inc. The presence of various pipeline products awaiting approval by the U.S. FDA and European Medicines Agency is one of the key attributes of this market. The first liposomal doxorubicin formulation was launched in 1995, namely Doxil/Caelyx by Janssen Products and LP & Myocet by Teva Pharmaceutical Laboratories. Doxil, the brand name of liposomal doxorubicin, is under development, and post its commercialization, the product is expected to create significant value over the next 3 to 4 years.

The increasing U.S. FDA approval for drug production is also anticipated to boost the market. The increasing indication of these drugs for various conditions such as AIDS-related Kaposi sarcoma, multiple myeloma, neuroblastoma, osteosarcoma, and ovarian cancer signifies the growth in demand. The technological advancements in the drugs formulations to overcome the adverse effects on health and also introduction of various types of medication delivery systems, such as coated nanoparticles, are some of the pivotal factors impelling the demand for the drug.

Liposomal doxorubicin is primarily approved for the treatment of myeloma, Kaposi sarcoma, and ovarian cancer. However, due to its wide usage in other conditions as well, in 2015, breast cancer accounted for the maximum revenue of 21.2%. The increasing prevalence of breast cancer is leading to growing demand for chemotherapy treatment, which accounts for the majority of revenue share. Besides breast carcinoma, ovarian cancer, multiple myeloma, and liver cancer also held a significant share in 2015. The use of doxorubicin for liver carcinoma treatment is rapidly growing, and this application is expected to grow with the fastest CAGR of 7.8% over the forecast period.

Liposomal Doxorubicin Market Report Highlights:

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Liposomal Doxorubicin Market Variables, Trends, & Scope

Chapter 4. Liposomal Doxorubicin Market: Product Estimates & Trend Analysis

Chapter 5. Liposomal Doxorubicin Market: Application Estimates & Trend Analysis

Chapter 6. Liposomal Doxorubicin Market: Distribution Channel Estimates & Trend Analysis

Chapter 7. Liposomal Doxorubicin Market: Regional Estimates & Trend Analysis

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â